Vertex Pharmaceuticals (VRTX) reached $470.1 at the closing of the latest trading day, reflecting a -1.17% change compared to ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Fintel reports that on January 28, 2026, Barclays upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.18% Upside As of ...

Fintel reports that on January 22, 2026, RBC Capital upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sector Perform to Outperform. Analyst Price Forecast Suggests 8.58% Upside ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.92, moving -2.36% from the previous trading session. This change lagged the S&P 500's daily gain of 0.26%. Elsewhere, the Dow ...